The U.S. Food and Drug Administration (FDA) announced on Wednesday that they would change the outdated labeling for mifepristone, the country’s most widely used abortion drug, a change that public health advocates and reproductive rights activists have campaigned for for more than a decade. “Today’s FDA announcement of a label change to mifepristone is a significant advancement for women in the United States,” said Amy Hagstrom Miller, the president of Whole Woman’s Health abortion clinics. “All of us are thrilled that the updated FDA labeling reflects evidence-based care that is best for women.”
In agreement with the latest scientific consensus, the FDA now instructs the dosage regimen that doctors have been following for years, prescribing 200 mg of mifepristone instead of 600 mg along with a higher dose of misoprostol, which is just as effective but has fewer side-effects. The outdated labeling had become fodder for anti-abortion activists, who were instrumental in passing several state laws, requiring patients to make up to three separate trips to a clinic (one for the dose of mifepristone, one for the dose of misoprostol, and one for a follow-up). This could now be limited to just one doctor’s visit. Vicki Saporta, the president of the National Abortion Federation, a group of providers which campaigned for the change, said on Wednesday that she was “delighted” that “politicians can no longer deny women access to this safe and effective method of early abortion care by insisting on an outdated regimen.”
Read the full story at The Guardian.